Research-Track Faculty

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James)

Pelotonia Institute for Immuno-Oncology (PIIO)

Seeks Research-Track Faculty to be a Technology Hub Leader in the Immune Monitoring and Discovery Platform (IMDP)

The OSUCCC-James Pelotonia Institute for Immuno-Oncology (PIIO) is seeking an innovative immune monitoring expert for research-track faculty positions with The Ohio State University (OSU). The successful candidate will lead one of the PIIO’s Immune Monitoring and Discovery Platform (IMDP) – Technology Hubs:

• Cell (Flow Cytometry)
• Tissue (Multispectral Imaging)
• Molecular (Immunogenomics)

The IMDP is paving the way for advanced immune phenotyping and functional analyses as well as multiplexed biomarker detection discovery methods (PMCIDs: PMC8716174, PMC8744064). The platform delivers cutting-edge technology to visualize the immune system’s response to cancer immunotherapy, with resources that include Flow Cytometry (Cytek Aurora Spectral Cell Sorter, Cytek Aurora Spectral Analyzer, Cytek Northern Lights, BD FACSMelody, Helios CyTOF); Multiplexed Imaging (Akoya PhenoImager HT, EVOS 7000); Single Cell Epigenetics (10X Genomics Chromium, Tapestation); Proteomics (Orbitrap Mass Spec). In addition, the IMDP educates investigators on advanced immune phenotyping and multiplex technologies and novel immunoassay reagent generation.

Leaders of each technology hub are expected to be technical experts in the respective domains with deep knowledge in immunology. Importantly, they are team science oriented and are highly collaborative. They are not expected to drive their own research interests (will not be independent investigators) but play instrumental roles in supporting the research mission of PIIO investigators. They will have demonstrated their productivity through authored publications of considerable interest and value to the field (e.g. favorable reviews and citations in the work of others), through presentations to professional societies, and/or contributed inventions, new designs, or techniques which are of material significance in the solution of important applied problems. Responsibilities include:

• collaborating with researchers on preclinical and clinical IO studies using immune monitoring tools and techniques
• developing, writing, budgeting, and submitting grant proposals of original research as co-investigator
• writing and submitting collaborative research manuscripts for publication in peer-reviewed journals.
• presenting research results at academic and international conferences
• advising researchers on new technology and trends in immune monitoring. Developing and conducting educational workshops
• training and supervising staff within the IMDP

Applicants must hold advanced degrees such as MD, DVM, PharmD, PhD, or MD/PhD. A postdoctoral fellowship in immunology, immuno-oncology, hematology, cancer genomics and/or pathobiology is required. Extensive experience leading or working with shared resource laboratories from one of these Technology Hubs is strongly preferred.

To apply: Send cover letter, CV, 2–3-page description of current and future research interests and contact information for three references via email to Tamra Brooks at [email protected].

About Us:

The PIIO is a comprehensive bench-to-bedside research initiative focused on harnessing the body’s immune system to fight cancer at all levels (https://cancer.osu.edu/piio). Launched in July 2019 as part of a $102 Million pledge from Pelotonia (pelotonia.org), the PIIO represents Ohio State’s commitment to grow the exciting area of immuno-oncology. Led by founding director and renowned immunologist Zihai Li, MD, PhD, the PIIO builds upon a rich portfolio of active investigator-initiated IO clinical trials being conducted at the OSUCCC – James.

Research in the PIIO centers on Systems IO (a systems-wide strategy to study the anti-cancer immune response holistically to discover the next IO breakthroughs and create effective cancer immunotherapies) and Translational IO (where we turn discoveries into new or improved cancer treatments and broaden the indications and patient populations that can be treated with cellular therapy). Our Immune Monitoring and Discovery Platform (IMDP) supports each center, providing comprehensive cell-based and molecule-based immunoassay services to support basic, translational, and clinical IO studies. The PIIO’s Immuno-Oncology Informatics Group (IOIG) provides data analytics for flow and mass cytometry, bulk and single-cell RNA-Seq, spatial transcriptomics and imaging, neoantigen discovery, and more.

The OSUCCC – James is a National Cancer Institute (NCI)-designated comprehensive cancer center, rated “Exceptional,” the highest rating given to cancer centers by the NCI; is one of only a few centers funded by the NCI to conduct phase I, II and III clinical trials on novel anticancer drugs; and includes the third-largest freestanding cancer hospital in the country. Ohio State is located in Columbus—a highly ranked, modern, affordable, friendly and diverse city. The Ohio State University is an EOE/AA/M/F/D/V employer.